Company Overview
Company Type: Public Company
Website: www.biocuretech.com
Number of Employees: -
Ticker: CURE (CNSX)
Year Founded: 2005


Business Description
Biocure Technology Inc., together with its subsidiary, engages in developing and commercializing biopharmaceutical technologies for use in recombinant and ranibizumab. The company is developing Interferons-β for the treatment of multiple sclerosis; Ranibizumab, a monoclonal antibody fragment for the treatment of macular degeneration, as well as to treat a type of eye problem known as macular edema; and Filgrastim to treat neutropenia, a lack of white blood cells caused by cancer, bone marrow transplant, chemotherapy, or by other conditions. It also engages in the research and development of CAR T Cell therapy that identifies and destroys cancer cells; a foot and mouth disease vaccine; and hair growth products. Biocure Technology Inc. was founded in 2005 and is headquartered in Vancouver, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
1.2
Total Enterprise Value
1.3
EBIT
(0.6)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
0.6x
Net Income
1.4
Total Debt
0.1
Price/Tang BV
0.5x
Total Assets
3.6
Currency in CAD in mm, LTM as of Jun-30-2023 TEV and Market Cap are calculated using a close price as of Sep-18-2023

Key Professionals
Name
Title
Cheng, Yee Sing
CEO & Director
Cochlovius, Björn 
President
Lichtenwald, Konstantin 
CFO, Corporate Secretary & Director
Nonni, Marco 
Consultant

Key Board Members
Name
Title
Cheng, Yee Sing
CEO & Director
Lichtenwald, Konstantin 
CFO, Corporate Secretary & Director
Kim, Sang Goo
Independent Director
Lee, Heon Ju
Member of Advisory Board
Lee, Hyun Soo
Member of Advisory Board
Shin, Jae Soo
Member of Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
1055 West Hastings Street Suite 300 | Vancouver, BC | V6E 2E9 | Canada
Phone: 604-609-7146   

Current and Pending Investors
Atriva Therapeutics GmbH (Pending), IBK Capital Corporation

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.02
Market Cap (mm)
1.2
Open
-
Shares Out. (mm)
81.6
Previous Close
 0.02
Float %
99.4%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
-/-
Diluted EPS Excl. Extra Items
0.02
52 wk High/Low
 0.10/ 0.0050
P/Diluted EPS Before Extra
0.64x
Volume (mm)
0.01
Avg 3M Dly Vlm (mm)
0.02
Beta 5Y
2.53


 
Delayed Quote** | Last Updated on Sep-18-2023 12:00 AM (GMT-5)
CNSX:CURE - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Gravis Energy Corp.
As of November 24, 2017, Gravis Energy Corp. was acquired by BiocurePharm, Inc. in a reverse merger transaction. Gravis Energy Corp., through its subsidiary, Gravis Capital Corp., explores for and develops mineral properties in Canada. It principally owns a 50% interest in the Waterbury Lake uranium property covering an area of 40,256 hectares located in the Athabasca Basin of Saskatchewan through its interest in the KEPCO Consortium. The company was formerly known as Sukari Ventures Corp. and changed its name to Gravis Energy Corp. in March 2010. Gravis Capital Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.

United States and Canada
Coal and Consumable Fuels
-
1.00
0.00
Atriva Therapeutics GmbH (Pending)
Atriva Therapeutics GmbH develops antiviral therapeutic against seasonal and pandemic influenza. It engages in development of ATR-002, a Mitogen-activated protein kinase inhibitor. The company was founded in 2015 and is based in Tübingen, Germany.

Europe
Pharmaceuticals
-
-
-
Biocurepharm Corporation
Biocurepharm Corporation operates as a biopharmaceutical company that develops and commercializes major biosimilar products. The company’s products include multiple sclerosis treatment drug that provides immune system attacks healthy cells and tissues as a chronic disease of the central nervous system; liqueur cell include recure cell hairgrowpac that helps to prevents the hair loss; recure cell pure whitening that provides skin whitening solution; recure cell pure cell anti-wrinkle drugs helps to moisturize the skin; CAR-T cell therapy drug that treat the tumor cells and defense in the body by specifically removes the cancer; macular degeneration treatment for ophthalmic disease to treat from visual acuity; and foot-and-mouth disease vaccine. The company was incorporated in 2005 and is based in Daejeon, South Korea.

Asia / Pacific
Biotechnology
-
-
-
Gravis Capital Corp.

United States and Canada
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-18-2023
-
Merger/Acquisition
Target
Biocure Technology Inc. (CNSX:CURE)
Atriva Therapeutics GmbH

-
Jan-30-2023
Jan-30-2023
Private Placement
Target
Biocure Technology Inc. (CNSX:CURE)


0.18
Jan-17-2023
Jan-17-2023
Private Placement
Target
Biocure Technology Inc. (CNSX:CURE)


0.04
Jan-16-2023
Jan-16-2023
Private Placement
Buyer
Biocurepharm Corporation
Biocure Technology Inc. (CNSX:CURE)

0.04
Dec-19-2022
May-31-2023
Merger/Acquisition
Seller
Biocurepharm Corporation

Biocure Technology Inc. (CNSX:CURE)
0.20
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Sep-18-2023
M&A Transaction Announcements
Atriva Therapeutics GmbH entered into a letter of intent to acquire Biocure Technology Inc. (CNSX:CURE).
Sep-08-2023
Executive/Board Changes - Other
Biocure Technology Inc. Announces Board of Director Changes
Sep-08-2023
Executive Changes - CEO
Biocure Technology Inc. Announces Chief Executive Officer Changes
Jul-05-2023
Executive/Board Changes - Other
Biocure Technology Inc. Announces Resignation of Berkan Unal from its Board of Directors
May-31-2023
M&A Transaction Closings
Sang Mok Lee acquired 46% of stake in BiocurePharm Corporation from Biocure Technology Inc. (CNSX:CURE).


Advisors
Most Recent Auditor
Dale Matheson Carr-Hilton LaBonte LLP


Most Recent Auditor
Dale Matheson Carr-Hilton


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 20, 2023 06:25 AM
CURE
Biocure Technology Inc
Reports
55
GlobalData

Sep 15, 2023 12:23 AM
CURE
Biocure Technology Inc (CURE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Jul 21, 2023 05:32 AM
CURE
Biocure Technology Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
28
GlobalData

Jun 19, 2023 05:38 AM
CURE
Biocure Technology Inc
Reports
55
GlobalData

Jun 09, 2023 04:46 AM
CURE
Biocure Technology Inc - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

May 23, 2023 04:28 AM
CURE
Biocure Technology Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
28
GlobalData

Mar 23, 2023 05:03 AM
CURE
Biocure Technology Inc (SKC.P.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
28
GlobalData

Mar 10, 2023 05:47 AM
CURE
Biocure Technology Inc (SKC.P.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
18
GlobalData

Mar 10, 2023 01:42 AM
CURE
Biocure Technology Inc (SKC.P.CVE) - Financial Analysis Review
Reports
64
GlobalData

Dec 12, 2022 04:49 AM
CURE
Biocure Technology Inc (SKC.P.CVE) - Financial Analysis Review
Reports
63


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Kim, Sang Goo

300,904

0.37

0.0

Jun-17-2022


Unal, Berkan 

112,000

0.14

0.0

Jun-17-2022


Lichtenwald B.B.A., CPA, CGA, Konstantin 

104,181

0.13

0.0

Nov-30-2022


Lee Ph.D., Sang Mok

0

0.00

0.0

May-31-2023



 



Top Buyers
No Top Buyers data available.

Top Sellers
Sellers
Common Stock Equivalent Held
Change
Lee Ph.D., Sang Mok
0
(27,317,506)


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
Date/Time
Headline
Source
Sep-14
Canadian Investment Regulatory Organization Trading Halt - CURE
Canada Newswire
Sep-08
CURE Biocure's Lee resigns as CEO, director
Canada StockWatch


Company Coverage
This company is not on any Coverage List.

Products
Biopharmaceutical Technologies, Minerals (Future)


Upcoming Events
Date/Time
Type
Nov-27-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-18-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Material Change Report
159 KB
Sep-18-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
News Releases
331 KB
Sep-10-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Material Change Report
125 KB
Aug-25-2023
Jun-30-2023
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Interim Financial Statements
480 KB
Jul-05-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
News Releases
178 KB
Jul-05-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Material Change Report
124 KB
Jun-02-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
News Releases
200 KB
Jun-02-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Securities Acquisition Filings (Early Warning)
200 KB
Jun-02-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Material Change Report
129 KB
Jun-02-2023
-
Biocure Technology Inc. (CNSX:CURE)
SEDAR
Securities Acquisition Filings (Early Warning)
201 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Lee Ph.D., Sang Mok (Founder, Former CEO & Director)
May-31-2023
Common Shares
(27,317,506)
-
Private Disposition
(100.00)
Multiple
Lichtenwald B.B.A., CPA, CGA, Konstantin  (CFO, Corporate Secretary & Director)
Nov-30-2022
Common Shares
(47,100)
(478)
Open Market Disposition
(31.13)
Multiple
Lee Ph.D., Sang Mok (Founder, Former CEO & Director)
Oct-16-2020
Common Shares
35,839
5,228
Private Acquisition
0.13
Exchange Announcement
Kim, Sang Goo (Independent Director)
Oct-16-2020
Common Shares
36,000
5,251
Private Acquisition
13.59
Exchange Announcement
Lichtenwald B.B.A., CPA, CGA, Konstantin  (CFO, Corporate Secretary & Director)
Oct-16-2020
Common Shares
36,000
5,251
Private Acquisition
324.32
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Cheng, Yee Sing
CEO & Director
(604) 339-0339
-
simonchengnow@gmail.com
Lichtenwald, Konstantin 
CFO, Corporate Secretary & Director
604-609-7146
-

Kim, Sang Goo
Independent Director
604-609-7146
-

Lee, Heon Ju
Member of Advisory Board
604-609-7146
-
-
Lee, Hyun Soo
Member of Advisory Board
604-609-7146
-
-
Shin, Jae Soo
Member of Advisory Board
604-609-7146
-
-
* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cheng, Yee Sing
CEO & Director
(604) 339-0339
-
simonchengnow@gmail.com
Cochlovius, Björn 
President
604-609-7146
-

Lichtenwald, Konstantin 
CFO, Corporate Secretary & Director
604-609-7146
-

Nonni, Marco 
Consultant
604-609-7146
-
-
* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
